GlobeNewswire: Bio-Path Holdings, Inc. Contains the last 10 of 164 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T01:27:37ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/08/2843016/0/en/Bio-Path-Holdings-Reports-Full-Year-2023-Financial-Results.html?f=22&fvtc=4&fvtv=28693Bio-Path Holdings Reports Full Year 2023 Financial Results2024-03-08T12:00:00Z<![CDATA[Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET]]>https://www.globenewswire.com/news-release/2024/03/01/2838733/0/en/Bio-Path-Holdings-to-Announce-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-March-8-2024.html?f=22&fvtc=4&fvtv=28693Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 20242024-03-01T12:00:00Z<![CDATA[HOUSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, March 8, 2024 at 8:30 a.m. ET to report financial results for the fourth quarter and full year ended December 31, 2023 and to provide a business overview.]]>https://www.globenewswire.com/news-release/2024/02/21/2832603/0/en/Bio-Path-Holdings-Announces-1-for-20-Reverse-Stock-Split.html?f=22&fvtc=4&fvtv=28693Bio-Path Holdings Announces 1-for-20 Reverse Stock Split2024-02-21T12:00:00Z<![CDATA[Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on February 23, 2024 Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on February 23, 2024]]>https://www.globenewswire.com/news-release/2024/01/10/2806973/0/en/Bio-Path-Holdings-Announces-Completion-of-First-Dose-Cohort-in-Phase-1-Clinical-Trial-Evaluating-BP1002-to-Treat-Refractory-Relapsed-Lymphoma-and-Refractory-Relapsed-Chronic-Lympho.html?f=22&fvtc=4&fvtv=28693Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients2024-01-10T12:00:00Z<![CDATA[Targeting Bcl-2 Protein Offers Potential Treatment for Patients Who Have Failed or Relapsed from Venetoclax-Based Frontline Therapy Targeting Bcl-2 Protein Offers Potential Treatment for Patients Who Have Failed or Relapsed from Venetoclax-Based Frontline Therapy]]>https://www.globenewswire.com/news-release/2023/12/14/2796128/0/en/Bio-Path-Holdings-Successfully-Completes-First-Dose-Cohort-of-Phase-1-1b-Clinical-Trial-of-BP1002-in-Refractory-Relapsed-Acute-Myeloid-Leukemia.html?f=22&fvtc=4&fvtv=28693Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia2023-12-14T12:00:00Z<![CDATA[BP1002 Offers Unique Opportunity for Venetoclax-Resistant Patients by Utilizing RNAi to Limit Cells’ Ability to Produce Bcl-2 Protein BP1002 Offers Unique Opportunity for Venetoclax-Resistant Patients by Utilizing RNAi to Limit Cells’ Ability to Produce Bcl-2 Protein]]>https://www.globenewswire.com/news-release/2023/11/15/2780902/0/en/Bio-Path-Holdings-Reports-Third-Quarter-2023-Financial-Results.html?f=22&fvtc=4&fvtv=28693Bio-Path Holdings Reports Third Quarter 2023 Financial Results2023-11-15T12:00:00Z<![CDATA[Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET]]>https://www.globenewswire.com/news-release/2023/11/08/2776042/0/en/Bio-Path-Holdings-to-Announce-Third-Quarter-2023-Financial-Results-on-November-15-2023.html?f=22&fvtc=4&fvtv=28693Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 20232023-11-08T12:00:00Z<![CDATA[HOUSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Wednesday, November 15, 2023 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2023 and to provide a business overview.]]>https://www.globenewswire.com/news-release/2023/10/24/2765453/0/en/Bio-Path-Holdings-to-Host-Virtual-Key-Opinion-Leader-Event-to-Discuss-Prexigebersen-and-Advances-in-the-Treatment-Landscape-for-Acute-Myeloid-Leukemia.html?f=22&fvtc=4&fvtv=28693Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia2023-10-24T11:00:00Z<![CDATA[Conference call to be held on Monday, October 30, 2023 at 9:00 a.m. ET Conference call to be held on Monday, October 30, 2023 at 9:00 a.m. ET]]>https://www.globenewswire.com/news-release/2023/09/08/2740314/0/en/Bio-Path-Holdings-to-Present-at-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html?f=22&fvtc=4&fvtv=28693Bio-Path Holdings to Present at H.C. Wainwright 25th Annual Global Investment Conference2023-09-08T20:01:00Z<![CDATA[HOUSTON, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter Nielsen, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright 25th Annual Global Investment Conference made available on Monday, September 11, 2023 at 7:00 a.m. ET.]]>https://www.globenewswire.com/news-release/2023/08/15/2725331/0/en/Bio-Path-Holdings-Reports-Second-Quarter-2023-Financial-Results.html?f=22&fvtc=4&fvtv=28693Bio-Path Holdings Reports Second Quarter 2023 Financial Results2023-08-15T11:00:00Z<![CDATA[Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET]]>